Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00372996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00372996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2007
Completion date
June 30, 2014
Enrollment
219 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms